**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 77520

**Manuscript Type:** REVIEW

**Liver transplantation for hepatocellular carcinoma: Historical evolution of transplantation criteria**

Ince V *et al*. Which are the best criteria for a LT?

Volkan Ince, Tevfik Tolga Sahin, Sami Akbulut, Sezai Yilmaz

**Volkan Ince, Tevfik Tolga Sahin, Sami Akbulut, Sezai Yilmaz,** Surgery and Liver Transplant Institute, Inonu University Faculty of Medicine, Malatya 44280, Turkey

**Sami Akbulut,** Biostatistics and Medical Informatics, Inonu University Faculty of Medicine, Malatya 44280, Turkey

**Author contributions:** Ince V, Akbulut S and Sahin TT conceived the project and designed research; Ince V, Akbulut S, Sahin TT and Yilmaz S wrote the manuscript and reviewed the final version.

**Corresponding author: Sami Akbulut, FACS, MD, PhD, Professor,** Surgery and Liver Transplant Institute, Inonu University Faculty of Medicine, Elazig Yolu 10 Km, Malatya 44280, Turkey. akbulutsami@gmail.com

**Received:** May 5, 2022

**Revised:** July 27, 2022

**Accepted:** August 25, 2022

**Published online:** October 16, 2022

**Abstract**

Liver transplantation (LT) for hepatocellular carcinoma is still a hot topic, and the main factor that is associated with the success of treatment is to determine the patients who will benefit from LT. Milan criteria have been defined 25 years ago and still is being used for patient selection for LT. However, in living donor LT, the Milan criteria is being extended. Current criteria for patient selection do not only consider morphologic characteristics such as tumor size and number of tumor nodules but also biologic markers that show tumor aggressiveness is also being considered. In the present review article, we have summarized all the criteria and scoring systems regarding LT for hepatocellular carcinoma. All criteria have 5-year overall survival rates that were comparable to the Milan Criteria and ranged between 60%-85%. On the other hand, it was seen that the recurrence rates had increased as the Milan criteria were exceeded; the 5-year recurrence rates ranged between 4.9% to 39.9%. Treatment of hepatocellular carcinoma needs a multidisciplinary approach. Ideal selection criteria are yet to be discovered. The same is true for treatment modalities. The goal will be achieved by a harmonic interplay between basic science researchers and clinicians.

**Key Words:** Liver transplantation; Hepatocellular carcinoma; Milan criteria; Expanded Malatya criteria

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Ince V, Sahin TT, Akbulut S, Yilmaz S. Liver transplantation for hepatocellular carcinoma: Historical evolution of transplantation criteria. *World J Clin Cases* 2022; 10(29): 10413-10427

**URL:** <https://www.wjgnet.com/2307-8960/full/v10/i29/10413.htm>

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i29.10413

**Core Tip:** Hepatocellular carcinoma is the third most common cause of cancer-related deaths. Liver transplantation has an important place in the treatment of hepatocellular carcinoma. However, there is no consensus on which patients should receive a liver transplantation. For this reason, various criteria have been defined. In this study, we will discuss the criteria defined by our liver transplant institute in light of a literature analysis.

**INTRODUCTION**

Currently, hepatocellular carcinoma (HCC) is the sixth most common cancer with 905677 new cases diagnosed annually. On the other hand, HCC is the third most common cause of cancer-related deaths causing 830180 deaths annually[1]. The main goal of treatment of patients with HCC is to provide prolonged and disease-free survival (DFS). Treatment options that will achieve this goal include many options, from minimally invasive interventional methods such as local regional treatments to highly complex treatment methods such as liver transplantation (LT). The success of treatment depends on the selection of patients that will benefit from the aggressive multimodality therapy. LT treats the underlying cirrhosis, and it is the gold standard treatment of the cancer. For LT, optimal patient selection criteria is the key to a successful outcome. Furthermore, living donor LT (LDLT) has revolutionized the treatment of HCC. LT from a living liver donor has a significant impact on patients with HCC. In patients with tumors within the Milan criteria, bridging procedures can be eliminated because patients do not have to wait on the deceased donor organ waiting list. On the other hand, in patients beyond the Milan criteria, the extended criteria can be chosen to optimally select the patient that will benefit most from the LT without risking the living donor. Since these patients do not have an impact on the waiting list, they can be rapidly transplanted. So far, this patient group has contributed to the accumulation of the data regarding the existing extended criteria that are available.

However, the demand for organs is overwhelmingly higher than the deceased donor organ supply. Therefore, using a valuable resource for patients with malignancy should be performed in accord with very strict criteria to choose the patient that will benefit the most from transplantation. In general, LT for any disease is considered acceptable if the 5-year survival rate is ≥ 50%[2,3]. Volk *et al*[4] stated that for HCC exceeding Milan criteria but within the University of California San Francisco (UCSF) criteria, the minimum overall 5-year survival rate requirement should be 61% so that it will not have a negative impact on other patients on the waiting list for non-malignant diseases. In 2020, the International Liver Transplantation Society Transplant Oncology consensus report stated that the minimum overall 5-year survival rate should be 60% for an acceptable result in LDLT for HCC[5].

However, the path from LT to definition of the current criteria has not been easy, and a lot of obstacles have been encountered and solutions have been developed. This resulted in development of diverse patient selection criteria and management protocols for approaching patients with HCC. Therefore, management of the patients with HCC up to the final point of LT forms the basis of all the auxiliary treatment methods including transarterial therapies, local ablative procedures and liver resections. The aim of the present review is to give a broad perspective regarding management of HCC prioritizing LT as the main treatment modality. Furthermore, we aimed to give a historical perspective regarding development of LT as a valid alternative for treatment of patients with HCC. Our main perspective is to convey our idea, which is that selection criteria that are and will be developed will never be ideal so they will be universally accepted. Therefore, our future perspectives are given at the end of our review to provide the future goals for the treatment of the disease in conjunction with LT.

**Historical Perspective: Development of the Patient Selection Criteria by Paul-Brousse Hospital and The evolution of Milan Criteria**

The first LT was performed 58 years ago. This was a revolutionary therapeutic modality bringing hope to the treatment of patients with end-stage liver disease[6]. Initial LTs were performed in patients with advanced stage liver tumors. Only 1 patient amongst the first 7 LTs performed was due to liver disease without any malignancy. The remaining patients were diagnosed with HCC (3 patients), unresectable colorectal cancer metastasis (1 patient) and cholangiocarcinoma (1 patient)[7]. However, the results of the transplant technique were initially very poor, and physicians in the field had to go back to basic science research to improve the transplant technique[7].

In 3 years, stable technique was established and longer survival rates exceeding 1 year were achieved. The results of these initial transplantations for HCC were not favorable. The longest survival was 400 d, and the patient died due to tumor recurrence. Initial dismal outcome after LT in patients with HCC resulted in the surgical community to declare that HCC was a contraindication for performing a LT[8]. However, studies on LT for HCC continued, and results showed that there was a correlation between the hepatic tumor burden and recurrence rates[9]. There were cornerstone studies showing efficacy and safety of LT in early-stage HCC[10]. LT provided a median overall survival of 16 mo (3-87 mo) in stage II HCC and 7.5 mo (2-20 mo) in stage III HCC[10]. First, definitive criteria were defined from Bismuth *et al*[11,12], and they have shown that less than 2 tumor nodules and a maximum tumor diameter less than 3 cm had lower recurrence when transplanted when compared to the resected patients. Criteria were named as the Paul-Brousse Hospital Criteria. LT using Paul-Brousse Hospital Criteria provided a 3-year DFS rate of 83%[12]. In the following years, Mazzaferro *et al*[13] defined the Milan criteria for selecting patients with HCC for LT. The Milan criteria includes tumors with no extrahepatic tumor involvement, without macroscopic portal vein invasion, solitary tumor ≤ 5 cm in diameter or a maximum of 3 tumors with each tumor diameter ≤ 3 cm. The patients with tumors that are within the Milan criteria had a 4-year overall survival rate of 85% following LT[13]. Currently, Milan criteria are used around the world to select patients with HCC for deceased donor LT (DDLT).

**Extending beyond the Milan Criteria: Expand or not to Expand?**

Milan criteria depend on morphologic parameters, and it only provides a chance for LT to 30% of the patients with HCC[14]. However, various observations have shown that there are patients with tumors that are beyond Milan criteria, who have favorable outcomes after LT[15]. The idea of expanding beyond the Milan criteria spread rapidly among the transplant community.

In 2001, Yao *et al*[16] developed the UCSF criteria to extend the Milan criteria for patients with HCC. These criteria also depended on the morphologic criteria such as maximal tumor diameter and number tumor nodules. The UCSF criteria included solitary tumors ≤ 6.5 cm or a maximum of 3 tumor nodules with each nodule ≤ 4.5 cm or sum of diameter of all tumors ≤ 8 cm. The 5-year overall survival rate was 75.2% in patients within UCSF criteria after LT. The UCSF criteria extended the Milan criteria by 10% without causing a significant decrease in the long-term survival rates. In 2007, internal validation of the UCSF criteria came from Yao *et al*[17] on 168 patients. The evaluation was preoperatively done by radiologic evaluation. Thirty-eight patients exceeded the Milan criteria but were within the UCSF criteria and 1- and 5-year recurrence free survival rates were 92.1% and 80.7%, respectively. External validation was performed by Duffy *et al*[18] in 2007 on a cohort of 467 patients. Preoperative imaging showed that 173 tumors (37%) were within the Milan criteria, 185 (40%) were beyond Milan criteria but within UCSF criteria and the remaining 109 (23%) were beyond the UCSF criteria. The results of the study showed that patients with tumors within the UCSF criteria and Milan criteria had comparable 5-year survival of 79% and 64%; while the patients with tumors exceeding the UCSF criteria had a 5-year survival less than 50%[18].

In 2002, Barcelona Clinic Liver Cancer criteria were defined, and these criteria included tumors with a solitary nodule ≤ 7 cm or 3 tumor nodules each ≤ 5 cm or 5 tumor nodules each ≤ 3 cm[19]. There were two novel recommendations in Barcelona Clinic Liver Cancer criteria: First was the emphasis of the feasibility of LDLT in HCC and the second was the importance of response to downstaging by locoregional therapy. Therefore, the Barcelona Clinic Liver Cancer criteria was the first to combine the morphometric measurements with the biologic behavior of the tumors. The reported 5-year overall survival rates were above 50%[19,20]. In their study, the results of LDLT for HCC were better than DDLT for patients receiving planned liver grafts after combined multimodality treatment, which is especially important for patients with tumor beyond the Milan criteria.

In fact, the majority of the extended criteria that have been discussed in the following section were defined by centers that perform LDLT at a high volume (Table 1)[21-45]. As the new biomarkers have been incorporated to use during the evaluation of the patients with HCC, it was realized that tumor biology was more important in determining the prognosis of patients with HCC following LT. Kyoto criteria was one of the first to incorporate morphologic characteristics of the tumor with laboratory parameters such as Des-carboxyprothrombin. Des-carboxyprothrombin is also named protein induced vitamin K absence or antagonist II (PIVKA-II) and is a marker predicting the biologic behavior of HCC[23]. In 2011, Toronto criteria were developed. According to these criteria, a pretransplant tumor biopsy is performed and regardless of the size and the number of the tumors, LT could be performed for patients with tumors that do not have poor differentiation, no microvascular invasion, and no extrahepatic extension of the disease[34]. In 2016 the same group defined the extended Toronto criteria, which included absence of cancer related symptoms to the criteria[35]. In 2019 and 2020, Shimamura *et al*[38] and Ichida *et al*[45] defined the 5-5-500 criteria, which included tumors with a diameter ≤ 5 cm, number of tumor nodules ≤ 5 and alpha fetoprotein (AFP) ≤ 500 ng/mL.

Inonu University in Malatya has the highest volume of LDLT in Europe, and we are working extensively in the multimodality treatment of HCC[39,40,46-49]. Our recent studies concentrated on development criteria expanding the Milan criteria. Our criteria were called Malatya and expanded Malatya criteria[39,40]. The Malatya criteria included tumor with a maximum diameter ≤ 6 cm, AFP ≤ 200 ng/mL, gamma-glutamyl transpeptidase (GGT) ≤ 104 U/L and well/moderate tumor differentiation. We defined GGT as a biomarker to predict the tumor biology for the first time in the literature, which was a novel approach[39,40]. Expansion of the Milan criteria was 42.7% in expanded Malatya criteria[40], 19.0% in 5-5-500 criteria[29], 10.0% in UCSF criteria and 27.0% in Malatya criteria[39]. Isoenzyme type II of GGT has previously been suggested to be a surrogate for differentiation in HCC; for the first time we have shown GGT to have prognostic significance for patients with HCC that have undergone LT[50-54]. In Malatya criteria, tumor differentiation is another component that determines the prognosis of the patients. However, the differentiation status of the tumors is very hard to predict in the preoperative period. As an alternative we are currently studying the response rate of the tumors to downstaging procedures, and we are investigating the role of positron emission tomography computed tomography (PET-CT) in predicting the level of tumor differentiation[39]. The response to downstaging locoregional therapies and its implications will be discussed in the following sections.

During the analysis phase of the Malatya criteria, we observed that there were patients beyond the Malatya criteria, yet they had good prognosis following LT. In subgroup analysis we grouped patients according to the tumor diameters. Patients with a tumor diameter greater than 6 cm were analyzed. We defined expanded Malatya criteria as tumors that have a maximum tumor diameter ≤ 10 cm, AFP ≤ 200 ng/mL and GGT ≤ 104 IU/mL (normal range, 12–64 IU/mL)[40]. In summary, by using the expanded Malatya criteria we have increased the maximum tumor diameter to 10 cm. The tumor differentiation was not significant in our univariate analysis during the definition of the expanded Malatya criteria.

All the criteria that are defined above have an acceptable level of long-term overall survival rates well above 50%. However, the survival of the patients differs in accordance with different selection criteria depending on the inclusion of patients with advanced tumors. Furthermore, we still do not have an ideal selection criterion that has universal validity. In addition, a biomarker that predicts the biologic behavior of the tumors such as microvascular invasion or differentiation is needed for thorough clinical evaluation of patients with HCC. Survival data of different criteria and scoring systems are summarized in Table 2.

**Scoring Systems**

Accumulating research has shown that many parameters have an impact on the prognosis of the patients. Among these parameters are morphologic parameters such as the number and size of the tumors, serum biomarkers such as AFP, Des-carboxyprothrombin (PIVKA II), GGT, inflammatory markers such as neutrophil to lymphocyte ratio and response to locoregional therapy. The selection criteria and scoring systems for HCC are similar in principle; they all predict the recurrence and survival of the patients following various treatment modalities[55-59]. The selection criteria are semi-quantitative determining high and low risk groups in terms of recurrence rates to determine whether the patient will benefit from a specific treatment modality, mainly LT[60]. However, scoring systems are more systematic and comprehensive. They define different stages of the disease that have different prognosis[60].

New scoring systems are being developed, combining all the above morphologic, biologic and inflammatory markers to optimize the selection of the patients with HCC for LT (Table 3). In 2012, Duvoux *et al*[55] from France defined a scoring system that they called the AFP model in which they incorporated AFP values to the morphologic characteristics such as tumor size and number. A score ≤ 2 was considered as low risk, and this scoring system is currently used for selecting patients with HCC for LT. Notarpaolo *et al*[60] validated the AFP model on a cohort of 574 patients. They showed that AFP score ≤ 2 *vs* > 2 was associated with 5-year recurrence rates of 13% *vs* 50%, respectively. Therefore, they showed that the AFP score well above 2 was 5 times more likely to develop recurrence in 5 years. The AFP model was validated by other researchers[60-64] and all reported similar results as Notarpaolo *et al*[60].

In 2017, the Risk Estimation of Tumor Recurrence After Liver Transplant (RETREAT) scoring system was defined, which included tumor burden, microvascular invasion and AFP values in the evaluation process. A score of 0 was associated with a 5-year recurrence rate < 3%, while a score > 5 was associated with a recurrence rate more than 75%[65]. This score has been validated by Abdelfattah *et al*[66] on a cohort of 73 patients who had tumors within Milan criteria. The results of the study showed that the Risk Estimation of Tumor Recurrence After Liver Transplant score> 5 was associated with a 67% recurrence rate and predicted the recurrence accurately.

Halazun *et al*[57] emphasized the importance of inflammatory markers in the prognosis of HCC. In 2017, they developed the MORAL scoring system, which included neutrophil to lymphocyte ratio as one of the prognostic factors. The objective of this scoring system was to determine the recurrence risk of the patients, and it had two components. The pre-MORAL component evaluated the largest tumor diameter (> 3 cm), neutrophil to lymphocyte ratio (> 5) and AFP (> 200 ng/dL). The post-MORAL component was dependent on the pathologic analysis such as largest tumor diameter (> 3 cm), number of tumor nodules (> 3), the tumor grade and presence of microvascular invasion. A score ≤ 2 was considered as low risk and the 5-year DFS rate was reported to be 97.4%. A score between 3 and 6 was considered as moderate risk and with a 5-year DFS rate of 75.1%. A score between 7 and 10 was considered as high risk and was associated with a 5-year DFS of 49.9%. A score above 10 had a very high risk of recurrence, and 5-year DFS was 22.1%.

In 2018, Halazun *et al*[58] defined the New York/California scoring system for selection of the patients with HCC for LT. They included the AFP response to locoregional therapy to the standard morphological criteria such as tumor size and number. A score between 0 and 2 was considered as low risk, and 5-year DFS was 90%. A score between 3 and 6 was considered as moderate risk, and the 5-year DFS was 70%. However, a score ≥ 7 was associated with a high risk of recurrence, and the 5-year DFS was 42%

Mazzaferro *et al*[59] developed the Metroticket 2.0 (AFP-adjusted-to-HCC size criteria) model in which they combined the serum AFP levels and Up-to-Seven scoring system. The low-risk group had an overall survival rate of 79.7% and a DFS of 89.6%. The most recent scoring system is from South Korea called SNAPP, which is an acronym for the tumor size, number, AFP, PIVKA II and PET-CT. This scoring system combined morphologic criteria, biologic markers and PET-CT findings. A score of 0-2 was defined as low risk, and 5-year DFS was 97%. A score of 3-4 was associated with a moderate risk of recurrence, and 5-year DFS was 71%. A score ≥ 5 was associated with a high risk of recurrence, and 5-year DFS was 31%[59].

The results of the scoring systems have shown that the efficacy depends on the advances in imaging systems and discovery of new biomarkers. Therefore, the transplant community needs basic science research in the field to meet these needs. Currently, there is no ideal scoring system/model that is universally validated for risk stratification of HCC.

**LDLT FOR HCC**

LDLT is an accepted treatment modality for end-stage liver disease. Furthermore, it is a very good alternative to DDLT[67]. LDLT has certain technical advantages over DDLT such as: (1) It provides an unlimited source of liver grafts; (2) Shorter cold/warm ischemia times providing better graft function and outcome; and (3) Since the source of the organ is a relative and they share similar genetic background, immunologically, LDLT is more favorable than DDLT[68].

In Turkey and many other Asian countries, deceased donor organ supply is limited, and LDLT is the only therapeutic option for many end-stage liver disease and liver cancer patients. There are two advantages of using living donor liver grafts: (1) It enables planning the timing of the transplant procedure; and (2) It is a “gift” from the relative that is exclusive for the patient. Therefore, the LDLT strategy enables planning of the sequential therapeutic modalities up to the point of LT. Furthermore, since the grafts are exclusive and readily available for the patients, Milan criteria can be expanded. Ideal selection criteria expanding the Milan criteria is especially important in the LDLT setting balancing the risks *vs* survival benefits in the recipient and the living donors. On the other hand, LDLT for patients with HCC is still controversial on many aspects. One aspect is the ethical dilemma to risk a healthy person for a recipient that has a fatal disease with a high risk of recurrence. Currently, the reported morbidity and mortality of living donor hepatectomy is 16% and 0.2%, respectively[69]. The second aspect of controversy is the high recurrence rates that are reported for LDLT[70,71]. These were attributed to rapid transplantation of patients receiving LDLT, which prevents selection process that is usually present during the listing period in DDLT. Therefore, biologically aggressive tumors are being transplanted rapidly in cases of LDLT. Furthermore, the regeneration process after the transplantation of the partial liver graft is thought to induce angiogenesis and tumor growth[70-74]. In addition, the LDLT is occasionally performed as a salvage procedure when other treatment modalities have failed, which means that more aggressive tumors are being transplanted[75]. Technically during LDLT, the long bile duct and hepatic artery are preserved for versatility of vasculobiliary complications, which may lead to higher tumor remnants that increase the risk of recurrence[71].

Despite these concerns that have been hypothesized, a meta-analysis published by Liang *et al*[76] in 2012 showed that in data of over 700 patients, the results of LDLT for HCC were comparable to that of DDLT in terms of recurrence rates and DFS. Furthermore, when considering the time spent on the waiting list and the risk of disease progression and drop-out, LDLT seems to be a feasible option for HCC provided that patient selection is performed accurately[24]. The results of LDLT and DDLT seems to be similar for tumors within Milan criteria, although Liang *et al*[76] reported that the 1-year recurrence rate was higher. The main issue is the feasibility of LDLT for tumors exceeding Milan criteria. A study by Hong *et al*[77] in 2016 reported that the annual rate of LDLT for extra-Milan or even very advanced stage HCC was increasing in Korea, and they showed that the low and intermediate risk group according to the Seoul National University criteria (low risk: AFP < 200 ng/mL and PET negative; intermediate risk: Either one is positive) for HCC within or beyond Milan criteria showed comparable 5-year DFS rates. Therefore, in countries where DDLT is limited due to limited organ supply, LDLT provides the means of transplantation of a higher number of patients with HCC; nevertheless, the biologic behavior of the tumors should be thoroughly evaluated[78]. As it can be seen from the data presented above, expansion of the Milan criteria and development of markers for tumor biology is especially important for LDLT for HCC. These controversies and discussions will continue until this goal is achieved.

**The Bridging and Downstaging Procedures**

The demand for organs exceeds the deceased organ supply, and therefore the number of patients on the waiting list is increasing. This causes an increased wait time on the list before a suitable organ is available[65,79]. Bridging procedures are neoadjuvant therapeutic options that will prevent disease progression during the waiting time on the list and will prevent drop out of the patients with HCC[8]. Downstaging procedures are performed to the tumors that are beyond Milan criteria to downstage them to the limits of the Milan criteria or to United Organ Sharing (UNOS) T2 stage[48,80]. The studies have shown that LT for tumors already within Milan criteria and tumors downstaged to Milan criteria show similar results[81,82]. There are many options for locoregional therapies (either bridging or downstaging) including radiofrequency ablation, microwave ablation, trans (hepatic) arterial embolization, transarterial chemoembolization and transarterial radioembolization with yttrium-90 microspheres[83].

UNOS uses a specific classification for HCC[17]. Downstaging is performed for tumors that exceed the UNOS T2 criteria (solitary 2 to 5 cm or 2 or 3 nodules, each nodule diameter < 3 cm) and must be in accord with one of the following: (1) Single lesion < 8 cm; (2) 2 to 3 lesions each < 5 cm and total tumor diameter < 8 cm; or (3) 4 to 5 lesions each < 3 cm and total tumor diameter < 8 cm. Cross-sectional imaging studies must confirm the absence of extrahepatic disease and macrovascular invasion[79]. One important issue to be discussed is the treatment options if decompensation of the patient occurs while the downstaging protocol is continuing. The UNOS protocol is very strict regarding this scenario, and it states that if the patient decompensates after or during locoregional therapy and if the follow-up period is not completed or if the tumor does not respond to the downstaging procedure, then the patients should be considered ineligible for LT[79].

**Future Directions**

The most effective treatment of HCC is LT. Furthermore, there is no ideal criterion that can be universally used. Since there is a shortage of the deceased donor organ pool, selection of the patients with HCC for DDLT should be performed in accord with strict criteria to provide maximum benefit from the transplanted organ. Milan criteria is the ideal selection criteria for centers performing DDLT[65]. This requires thorough evaluation of the biologic behavior of the tumor using various biologic markers such as AFP, AFPL3 and PIVKA II, imaging studies such as positron emission tomography and response to various locoregional downstaging procedures[65].None of the criteria using these parameters are proven to effective[84,85]. Therefore, the future lies in development of effective systemic therapies and strategies for evaluation of the tumor biology[85]. In particular, research in the genomic analysis of different phenotypes that increases the understanding of hepatic carcinogenesis should be pursued. This will allow researchers to develop targeted therapies that will be used in the neoadjuvant or adjuvant setting. Advancements in the software, imaging and advanced technologies such as radiomics provide accurate diagnosis and staging of the disease in the pretransplant period. This will increase the accuracy of patient selection. Perhaps newer selection criteria will be defined[86]. Genomics will also aid advancements in liquid biopsy, which will be effective for staging of the tumors[87-89]. Genomics can also provide information regarding biologic behavior of the tumors and will introduce a whole new era of patient evaluation and personalized medicine.

The future of cancer treatment depends on the advancements in basic science research. HCC is a typical example of the bench to clinical applications[90]. It has been shown that epidermal growth factor pathway is activated in HCC, and this results in activation of the tyrosine kinase system, which is a transcriptional hub for activation of the multiple growth factor pathways[90]. Furthermore, mitogen activated protein kinase has been shown to activate the vascular endothelial growth factor-dependent angiogenic switch in HCC[91,92]. All these give the physicians possibilities of small molecule targets for molecularly targeted new therapies. Sorafenib was one of the effective targeted therapies developed for HCC. It is a multikinase inhibitor targeting the vascular endothelial growth factor and platelet-derived growth factor pathways[93,94].

Epigenetic changes control the invasion and metastasis in HCC. This implies that the microvascular invasion capabilities are controlled by epigenetic mechanisms. These mechanisms include hyper-/hypomethylation of the DNA, histone associated mechanisms and non-coding RNA. These can be used as diagnostic tools or can give an idea regarding the prognosis of the patients[95,96]. For example, it has been shown that hypermethylation of RASSF1A has been associated with tumor growth and progression that is independent from AFP levels and has been proposed as a diagnostic marker in high risk groups[97]. On the other hand, many epigenetic markers, such as miR-122, EZH2, SUV39HZ, ARK-1 and ARK-2, have been studied showing strong correlation with poor prognosis[98-100]. These may provide the future of selection criteria for determining ideal patients for liver transplant.

One of the novel developments in the treatment of cancer is development of oncolytic viral therapy. Oncolytic viral therapies use genetically engineered or naturally occurring deficient viruses that can only replicate and kill cells with active mitosis. They cause viral oncolysis through the replication cycle and induce potent anti-tumor immunity. Some of them have been approved for the treatment of HCC. Among them is vaccinia virus JX-594 (Pexastimogene Devacirepvec) for HCC[101].

The cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein-1 pathway is activated in HCC[102,103]. Therefore, the microenvironment of HCC favors immune evasion. All these have prognostic significance for patients with HCC. The clinical trials using anti-cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein-1 antagonists have started; initial reports show a high rate of adverse effects with marginal improvement in patient survival[104]. However, continuing research will lead to development of more effective and specific therapeutic strategies.

Irreversible electroporation has been a new development for locoregional therapy of solid organ tumors. It is performed percutaneously, and electrical pulses are sent to the tissues generating pores in the cancer cell membrane, which leads to apoptosis[105,106]. It has minimal damage to the surrounding tissue. For this reason, it can be considered in tumors that are in close proximity to vascular structures[106]. It has been shown that irreversible electroporation provides complete response in 97% of the patients with tumors less than 3 cm[107,108]. Nevertheless, efficacy is reduced in tumors greater than 4 cm. There have been reports confirming the efficacy and safety of the procedure by leading to faster recovery and less liver damage[109].

There is still much to achieve in the treatment of HCC. LT is just one end of the spectrum. The main benefit will be obtained from therapies in the neoadjuvant and adjuvant setting to provide a better survival and reduced recurrence for patients transplanted for HCC curative treatment. Therefore, development of new therapeutics and new criteria/markers for thorough evaluation of the patients with HCC should be evaluated in the same context, and equivocal advancements should be performed in both areas to provide a favorable outcome in this aggressive tumor.

**CONCLUSION**

LT in HCC is still a hot topic with many controversies. We still need ideal selection criteria and prognostic scores to evaluate patients for LT and other adjuvant therapies. However, we may not achieve this goal for this is a very heterogenous tumor and none of the developed criteria will be ideal. It shows geographic diversities according to race and the established strategy of organ transplantation (LDLT *vs* DDLT). Achievements in therapeutic modalities are needed to develop effective treatment of the patients to achieve acceptable overall survival and DFS rates. Hence, a multidisciplinary approach is required for management of HCC. The basic science research seems to be the backbone of all the expectations in the field.

**REFERENCES**

1 **Global Cancer Observatory**. Globocan 2020. Dec 2020. [cited 10 March 2022]. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf

2 **Neuberger J**, James O. Guidelines for selection of patients for liver transplantation in the era of donor-organ shortage. *Lancet* 1999; **354**: 1636-1639 [PMID: 10560692 DOI: 10.1016/S0140-6736(99)90002-8]

3 **Bruix J**, Fuster J, Llovet JM. Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. *Liver Transpl* 2003; **9**: 700-702 [PMID: 12827556 DOI: 10.1053/jlts.2003.50124]

4 **Volk ML**, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. *Am J Transplant* 2008; **8**: 839-846 [PMID: 18318783 DOI: 10.1111/j.1600-6143.2007.02138.x]

5 **Mehta N**, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. *Transplantation* 2020; **104**: 1136-1142 [PMID: 32217938 DOI: 10.1097/TP.0000000000003174]

6 **Fricker J**. Thomas Starzl. *BMJ* 2017; **357**: j1806 [PMID: 28400419 DOI: 10.1136/bmj.j1806]

7 **McKenna GJ,** Klintmalm GBG. The History of Liver Transplantation. In:Busuttil RW, Klintmalm GBG eds. Transplantation of The Liver. 3rd ed. Philadelphia: Elsevier Saunders, 2015: 2-22

8 **Onaca N,** Stone MJ, Fulmer MJ, Klintmalm GBG. Transplantation for Primary Hepatic Malignancy. In:Busuttil RW, Klintmalm GBG eds. Transplantation of The Liver. 3rd ed. Philadelphia: Elsevier Saunders, 2015: 189-204

9 **Saidi RF**, Hejazi Kenari SK. Liver transplantation for hepatocellular carcinoma: past, present and future. *Middle East J Dig Dis* 2013; **5**: 181-192 [PMID: 24829690]

10 **Ismail T**, Angrisani L, Gunson BK, Hübscher SG, Buckels JA, Neuberger JM, Elias E, McMaster P. Primary hepatic malignancy: the role of liver transplantation. *Br J Surg* 1990; **77**: 983-987 [PMID: 2169946 DOI: 10.1002/bjs.1800770908]

11 **Bismuth H**, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. *Semin Liver Dis* 1999; **19**: 311-322 [PMID: 10518310 DOI: 10.1055/s-2007-1007120]

12 **Bismuth H**, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. *Ann Surg* 1993; **218**: 145-151 [PMID: 8393649 DOI: 10.1097/00000658-199308000-00005]

13 **Mazzaferro V**, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; **334**: 693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104]

14 **Lingiah VA**, Niazi M, Olivo R, Paterno F, Guarrera JV, Pyrsopoulos NT. Liver Transplantation Beyond Milan Criteria. *J Clin Transl Hepatol* 2020; **8**: 69-75 [PMID: 32274347 DOI: 10.14218/JCTH.2019.00050]

15 **Cascales-Campos P**, Martinez-Insfran LA, Ramirez P, Ferreras D, Gonzalez-Sanchez MR, Sanchez-Bueno F, Robles R, Pons JA, Capel A, Parrilla P. Liver Transplantation in Patients With Hepatocellular Carcinoma Outside the Milan Criteria After Downstaging: Is It Worth It? *Transplant Proc* 2018; **50**: 591-594 [PMID: 29579861 DOI: 10.1016/j.transproceed.2017.09.063]

16 **Yao FY**, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. *Hepatology* 2001; **33**: 1394-1403 [PMID: 11391528 DOI: 10.1053/jhep.2001.24563]

17 **Yao FY**, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. *Am J Transplant* 2007; **7**: 2587-2596 [PMID: 17868066 DOI: 10.1111/j.1600-6143.2007.01965.x]

18 **Duffy JP**, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, Yersiz H, Lu DS, Lassman C, Tong MJ, Hiatt JR, Busuttil RW. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. *Ann Surg* 2007; **246**: 502-9; discussion 509-11 [PMID: 17717454 DOI: 10.1097/SLA.0b013e318148c704]

19 **Bruix J**, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. *Hepatology* 2002; **35**: 519-524 [PMID: 11870363 DOI: 10.1053/jhep.2002.32089]

20 **Llovet JM**, Pavel M, Rimola J, Diaz MA, Colmenero J, Saavedra-Perez D, Fondevila C, Ayuso C, Fuster J, Ginès P, Bruix J, Garcia-Valdecasas JC. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). *Liver Transpl* 2018; **24**: 369-379 [PMID: 29140601 DOI: 10.1002/lt.24977]

21 **Kneteman NM**, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, Wong WW, Gutfreund K, Mason AL, Jewell LD, Shapiro AM, Bain VG, Bigam DL. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. *Liver Transpl* 2004; **10**: 1301-1311 [PMID: 15376305 DOI: 10.1002/Lt.20237]

22 **Jonas S**, Mittler J, Pascher A, Schumacher G, Theruvath T, Benckert C, Rudolph B, Neuhaus P. Living donor liver transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center. *Liver Transpl* 2007; **13**: 896-903 [PMID: 17538994 DOI: 10.1002/Lt.21189]

23 **Ito T**, Takada Y, Ueda M, Haga H, Maetani Y, Oike F, Ogawa K, Sakamoto S, Ogura Y, Egawa H, Tanaka K, Uemoto S. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. *Liver Transpl* 2007; **13**: 1637-1644 [PMID: 18044766 DOI: 10.1002/lt.21281]

24 **Sugawara Y**, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. *Dig Dis* 2007; **25**: 310-312 [PMID: 17960065 DOI: 10.1159/000106910]

25 **Onaca N**, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. *Liver Transpl* 2007; **13**: 391-399 [PMID: 17318865 DOI: 10.1002/lt.21095]

26 **Zheng SS**, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. *Transplantation* 2008; **85**: 1726-1732 [PMID: 18580463 DOI: 10.1097/TP.0b013e31816b67e4]

27 **Lee SG**, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, Ko GY, Park KM, Ha TY, Song GW. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. *Liver Transpl* 2008; **14**: 935-945 [PMID: 18581465 DOI: 10.1002/lt.21445]

28 **Herrero JI**, Sangro B, Pardo F, Quiroga J, Iñarrairaegui M, Rotellar F, Montiel C, Alegre F, Prieto J. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. *Liver Transpl* 2008; **14**: 272-278 [PMID: 18306328 DOI: 10.1002/lt.21368]

29 **Silva M**, Moya A, Berenguer M, Sanjuan F, López-Andujar R, Pareja E, Torres-Quevedo R, Aguilera V, Montalva E, De Juan M, Mattos A, Prieto M, Mir J. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. *Liver Transpl* 2008; **14**: 1449-1460 [PMID: 18825681 DOI: 10.1002/lt.21576]

30 **Fan J**, Yang GS, Fu ZR, Peng ZH, Xia Q, Peng CH, Qian JM, Zhou J, Xu Y, Qiu SJ, Zhong L, Zhou GW, Zhang JJ. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. *J Cancer Res Clin Oncol* 2009; **135**: 1403-1412 [PMID: 19381688 DOI: 10.1007/s00432-009-0584-6]

31 **Taketomi A**, Sanefuji K, Soejima Y, Yoshizumi T, Uhciyama H, Ikegami T, Harada N, Yamashita Y, Sugimachi K, Kayashima H, Iguchi T, Maehara Y. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. *Transplantation* 2009; **87**: 531-537 [PMID: 19307789 DOI: 10.1097/TP.0b013e3181943bee]

32 **Mazzaferro V**, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P; Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. *Lancet Oncol* 2009; **10**: 35-43 [PMID: 19058754 DOI: 10.1016/S1470-2045(08)70284-5]

33 **Toso C**, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. *Hepatology* 2009; **49**: 832-838 [PMID: 19152426 DOI: 10.1002/hep.22693]

34 **DuBay D**, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS, McGilvray I, Ghanekar A, Selzner M, Greig PD, Grant DR. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. *Ann Surg* 2011; **253**: 166-172 [PMID: 21294289 DOI: 10.1097/sla.0b013e31820508f1]

35 **Sapisochin G**, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, Cleary SP, Lilly L, Cattral MS, Marquez M, Selzner M, Renner E, Selzner N, McGilvray ID, Greig PD, Grant DR. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. *Hepatology* 2016; **64**: 2077-2088 [PMID: 27178646 DOI: 10.1002/hep.28643]

36 **Lai Q**, Avolio AW, Manzia TM, Sorge R, Agnes S, Tisone G, Berloco PB, Rossi M. Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation. *Clin Transplant* 2012; **26**: E125-E131 [PMID: 22192083 DOI: 10.1111/j.1399-0012.2011.01572.x]

37 **Kim JM**, Kwon CH, Joh JW, Park JB, Lee JH, Kim GS, Kim SJ, Paik SW, Lee SK. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma. *Transplant Proc* 2014; **46**: 726-729 [PMID: 24767334 DOI: 10.1016/j.transproceed.2013.11.037]

38 **Shimamura T**, Akamatsu N, Fujiyoshi M, Kawaguchi A, Morita S, Kawasaki S, Uemoto S, Kokudo N, Hasegawa K, Ohdan H, Egawa H, Furukawa H, Todo S; Japanese Liver Transplantation Society. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule – a retrospective study. *Transpl Int* 2019; **32**: 356-368 [PMID: 30556935 DOI: 10.1111/tri.13391]

39 **Ince V**, Akbulut S, Otan E, Ersan V, Karakas S, Sahin TT, Carr BI, Baskiran A, Samdanci E, Bag HG, Koc C, Usta S, Ozdemir F, Barut B, Gonultas F, Sarici B, Kutluturk K, Dogan MS, Ozgor D, Dikilitas M, Harputluoglu M, Aladag M, Kutlu R, Varol I, Dirican A, Aydin C, Isik B, Ara C, Kayaalp C, Emre S, Yilmaz S. Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded Criteria. *J Gastrointest Cancer* 2020; **51**: 998-1005 [PMID: 32519232 DOI: 10.1007/s12029-020-00424-w]

40 **Ince V**, Carr BI, Bag HG, Ersan V, Usta S, Koc C, Gonultas F, Sarici BK, Karakas S, Kutluturk K, Baskiran A, Yilmaz S. Liver transplant for large hepatocellular carcinoma in Malatya: The role of gamma glutamyl transferase and alpha-fetoprotein, a retrospective cohort study. *World J Gastrointest Surg* 2020; **12**: 520-533 [PMID: 33437403 DOI: 10.4240/wjgs.v12.i12.520]

41 **Kaido T**, Ogawa K, Mori A, Fujimoto Y, Ito T, Tomiyama K, Takada Y, Uemoto S. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. *Surgery* 2013; **154**: 1053-1060 [PMID: 24074704 DOI: 10.1016/j.surg.2013.04.056]

42 **Kamo N**, Kaido T, Yagi S, Okajima H, Uemoto S. Liver Transplantation for Intermediate-Stage Hepatocellular Carcinoma. *Liver Cancer* 2018; **7**: 179-189 [PMID: 29888207 DOI: 10.1159/000487058]

43 **Lei JY**, Wang WT, Yan LN. Up-to-seven criteria for hepatocellular carcinoma liver transplantation: a single center analysis. *World J Gastroenterol* 2013; **19**: 6077-6083 [PMID: 24106409 DOI: 10.3748/wjg.v19.i36.6077]

44 **Martino MD**, Lai Q, Lucatelli P, Damato E, Calabrese A, Catalano C. Comparison of Up-to-seven criteria with Milan Criteria for liver transplantation in patients with HCC. *Trend Transp* 2021; 14 [DOI: 10.15761/TiT.1000300]

45 **Ichida A**, Akamatsu N, Hasegawa K. Validation of novel Japanese indication criteria and biomarkers among living donor liver transplantation recipients with hepatocellular carcinoma – a single center retrospective study. *Hepatoma Res* 2020; **6:** 54 [DOI: 10.20517/2394-5079.2020.59]

46 **Isik B**, Ince V, Karabulut K, Kayaalp C, Yilmaz S. Living donor liver transplantation for hepatocellular carcinoma. *Transplant Proc* 2012; **44**: 1713-1716 [PMID: 22841251 DOI: 10.1016/j.transproceed.2012.05.033]

47 **Kayaalp C**, Ince V, Ersan V, Karakas S, Kahraman AS, Yilmaz S. Liver Transplantation for Hepatocellular Carcinoma at Inonu University. *J Gastrointest Cancer* 2017; **48**: 268-271 [PMID: 28674912 DOI: 10.1007/s12029-017-9965-2]

48 **Kutlu R**, Karatoprak S. Radioembolization for Hepatocellular Carcinoma in Downstaging and Bridging for Liver Transplantation. *J Gastrointest Cancer* 2020; **51**: 1157-1164 [PMID: 32880041 DOI: 10.1007/s12029-020-00492-y]

49 **Ince V**, Ersan V, Karakas S, Kutluturk K, Karadag N, Kutlu R, Yilmaz S. Does Preoperative Transarterial Chemoembolization for Hepatocellular Carcinoma Increase the Incidence of Hepatic Artery Thrombosis After Living-Donor Liver Transplant? *Exp Clin Transplant* 2017; **15**: 21-24 [PMID: 28301994 DOI: 10.6002/ect.TOND16.L7]

50 **Wang NY**, Zhang D, Zhao W, Fang GX, Shi YL, Duan MH. Clinical application of an enzyme-linked immunosorbent assay detecting hepatoma-specific gamma-glutamyltransferase. *Hepatol Res* 2009; **39**: 979-987 [PMID: 19624768 DOI: 10.1111/j.1872-034X.2009.00538.x]

51 **Yao DF**, Dong ZZ, Yao M. Specific molecular markers in hepatocellular carcinoma. *Hepatobiliary Pancreat Dis Int* 2007; **6**: 241-247 [PMID: 17548245]

52 **Xia J**, Song P, Sun Z, Sawakami T, Jia M, Wang Z. Advances of diagnostic and mechanistic studies of γ-glutamyl transpeptidase in hepatocellular carcinoma. *Drug Discov Ther* 2016; **10**: 181-187 [PMID: 27534452 DOI: 10.5582/ddt.2016.01052]

53 **Carr BI**, Ince V, Bag HG, Ersan V, Usta S, Yilmaz S. Microscopic vascular invasion by hepatocellular carcinoma in liver transplant patients. *Clin Pract (Lond)* 2020; **17**: 1497-1505 [PMID: 33343877]

54 **Ince V**, Carr BI, Bag HG, Koc C, Usta S, Ersan V, Baskiran A, Sahin TT, Yilmaz S. Gamma glutamyl transpeptidase as a prognostic biomarker in hepatocellular cancer patients especially with >5 cm tumors, treated by liver transplantation. *Int J Biol Markers* 2020; **35**: 91-95 [PMID: 32436751 DOI: 10.1177/1724600820921869]

55 **Duvoux C**, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, Compagnon P, Vanlemmens C, Dumortier J, Dharancy S, Gugenheim J, Bernard PH, Adam R, Radenne S, Muscari F, Conti F, Hardwigsen J, Pageaux GP, Chazouillères O, Salame E, Hilleret MN, Lebray P, Abergel A, Debette-Gratien M, Kluger MD, Mallat A, Azoulay D, Cherqui D; Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. *Gastroenterology* 2012; **143**: 986-94.e3; quiz e14-5 [PMID: 22750200 DOI: 10.1053/j.gastro.2012.05.052]

56 **Mehta N**, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. *JAMA Oncol* 2017; **3**: 493-500 [PMID: 27838698 DOI: 10.1001/jamaoncol.2016.5116]

57 **Halazun KJ**, Najjar M, Abdelmessih RM, Samstein B, Griesemer AD, Guarrera JV, Kato T, Verna EC, Emond JC, Brown RS Jr. Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story. *Ann Surg* 2017; **265**: 557-564 [PMID: 27611615 DOI: 10.1097/SLA.0000000000001966]

58 **Halazun KJ**, Tabrizian P, Najjar M, Florman S, Schwartz M, Michelassi F, Samstein B, Brown RS Jr, Emond JC, Busuttil RW, Agopian VG. Is it Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies. *Ann Surg* 2018; **268**: 690-699 [PMID: 30048307 DOI: 10.1097/SLA.0000000000002964]

59 **Mazzaferro V**, Sposito C, Zhou J, Pinna AD, De Carlis L, Fan J, Cescon M, Di Sandro S, Yi-Feng H, Lauterio A, Bongini M, Cucchetti A. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. *Gastroenterology* 2018; **154**: 128-139 [PMID: 28989060 DOI: 10.1053/j.gastro.2017.09.025]

60 **Notarpaolo A**, Layese R, Magistri P, Gambato M, Colledan M, Magini G, Miglioresi L, Vitale A, Vennarecci G, Ambrosio CD, Burra P, Di Benedetto F, Fagiuoli S, Colasanti M, Maria Ettorre G, Andreoli A, Cillo U, Laurent A, Katsahian S, Audureau E, Roudot-Thoraval F, Duvoux C. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. *J Hepatol* 2017; **66**: 552-559 [PMID: 27899297 DOI: 10.1016/j.jhep.2016.10.038]

61 **Rhu J**, Kim JM, Choi GS, Kwon CHD, Joh JW. Validation of the α-fetoprotein Model for Hepatocellular Carcinoma Recurrence After Transplantation in an Asian Population. *Transplantation* 2018; **102**: 1316-1322 [PMID: 29470357 DOI: 10.1097/TP.0000000000002136]

62 **Li WF**, Yen YH, Liu YW, Wang CC, Yong CC, Lin CC, Cheng YF, Wang JH. Validation of an alpha-fetoprotein model to predict recurrence after liver resection for hepatocellular carcinoma. *Updates Surg* 2022; **74**: 1345-1352 [PMID: 34374920 DOI: 10.1007/s13304-021-01147-8]

63 **Degroote H**, Callebout E, Iesari S, Dekervel J, Schreiber J, Pirenne J, Verslype C, Ysebaert D, Michielsen P, Lucidi V, Moreno C, Detry O, Delwaide J, Troisi RI, Lerut JP, Van Vlierberghe H; Be-LIAC. Extended criteria for liver transplantation in hepatocellular carcinoma. A retrospective, multicentric validation study in Belgium. *Surg Oncol* 2020; **33**: 231-238 [PMID: 31630912 DOI: 10.1016/j.suronc.2019.10.006]

64 **Mourad M**, Lebossé F, Merle P, Levrero M, Antonini T, Lesurtel M, Ducerf C, Zoulim F, Mabrut JY, Mohkam K. External validation of the French alpha-fetoprotein model for hepatocellular carcinoma liver transplantation in a recent unicentric cohort – a retrospective study. *Transpl Int* 2021; **34**: 535-545 [PMID: 33449394 DOI: 10.1111/tri.13819]

65 **Mehta N**, Yao FY. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma? *Clin Liver Dis (Hoboken)* 2019; **13**: 20-25 [PMID: 31168361 DOI: 10.1002/cld.793]

66 **Abdelfattah MR**, El-Haddad HM, Elsiesy H. Validation of Risk Estimation of Tumor Recurrence After Transplant Score in Patients With Hepatocellular Carcinoma Treated by Liver Transplant. *Exp Clin Transplant* 2021; **19**: 1298-1302 [PMID: 34951348 DOI: 10.6002/ect.2021.0378]

67 **Kaihara S**, Kiuchi T, Ueda M, Oike F, Fujimoto Y, Ogawa K, Kozaki K, Tanaka K. Living-donor liver transplantation for hepatocellular carcinoma. *Transplantation* 2003; **75**: S37-S40 [PMID: 12589138 DOI: 10.1097/01.TP.0000047029.02806.16]

68 **Zimmerman MA**, Trotter JF. Living donor liver transplantation in patients with hepatitis C. *Liver Transpl* 2003; **9**: S52-S57 [PMID: 14586896 DOI: 10.1053/jlts.2003.50256]

69 **Intaraprasong P**, Sobhonslidsuk A, Tongprasert S. Donor outcomes after living donor liver transplantation (LDLT). *J Med Assoc Thai* 2010; **93**: 1340-1343 [PMID: 21114217]

70 **Kulik L**, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. *Gastroenterology* 2004; **127**: S277-S282 [PMID: 15508095 DOI: 10.1053/j.gastro.2004.09.042]

71 **Marcos A**, Fisher RA, Ham JM, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Fulcher AS, Posner MP. Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation. *Transplantation* 2000; **69**: 1375-1379 [PMID: 10798757 DOI: 10.1097/00007890-200004150-00028]

72 **Man K**, Lo CM, Xiao JW, Ng KT, Sun BS, Ng IO, Cheng Q, Sun CK, Fan ST. The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation. *Ann Surg* 2008; **247**: 1049-1057 [PMID: 18520234 DOI: 10.1097/SLA.0b013e31816ffab6XXX]

73 **Man K**, Lo CM, Lee TK, Li XL, Ng IO, Fan ST. Intragraft gene expression profiles by cDNA microarray in small-for-size liver grafts. *Liver Transpl* 2003; **9**: 425-432 [PMID: 12682897 DOI: 10.1053/jlts.2003.50066]

74 **Yang ZF**, Poon RT, Luo Y, Cheung CK, Ho DW, Lo CM, Fan ST. Up-regulation of vascular endothelial growth factor (VEGF) in small-for-size liver grafts enhances macrophage activities through VEGF receptor 2-dependent pathway. *J Immunol* 2004; **173**: 2507-2515 [PMID: 15294966 DOI: 10.4049/jimmunol.173.4.2507]

75 **Yao FY**, Hirose R, LaBerge JM, Davern TJ 3rd, Bass NM, Kerlan RK Jr, Merriman R, Feng S, Freise CE, Ascher NL, Roberts JP. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. *Liver Transpl* 2005; **11**: 1505-1514 [PMID: 16315294 DOI: 10.1002/Lt.20526]

76 **Liang W**, Wu L, Ling X, Schroder PM, Ju W, Wang D, Shang Y, Kong Y, Guo Z, He X. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis. *Liver Transpl* 2012; **18**: 1226-1236 [PMID: 22685095 DOI: 10.1002/lt.23490]

77 **Hong SK**, Lee KW, Kim HS, Yoon KC, Yi NJ, Suh KS. Living donor liver transplantation for hepatocellular carcinoma in Seoul National University. *Hepatobiliary Surg Nutr* 2016; **5**: 453-460 [PMID: 28123999 DOI: 10.21037/hbsn.2016.08.07]

78 **Yoon YI**, Lee SG. Living Donor Liver Transplantation for Hepatocellular Carcinoma: An Asian Perspective. *Dig Dis Sci* 2019; **64**: 993-1000 [PMID: 30895483 DOI: 10.1007/s10620-019-05551-4]

79 **Pavel MC**, Fuster J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. *World J Gastroenterol* 2018; **24**: 3626-3636 [PMID: 30166858 DOI: 10.3748/wjg.v24.i32.3626]

80 **Wehrenberg-Klee E**, Gandhi RT, Ganguli S. Patient Selection and Clinical Outcomes of Y90 in Hepatocellular Carcinoma. *Tech Vasc Interv Radiol* 2019; **22**: 70-73 [PMID: 31079713 DOI: 10.1053/j.tvir.2019.02.006]

81 **Tabone M**, Calvo A, Russolillo N, Langella S, Carbonatto P, Lo Tesoriere R, Richetta E, Pellerito R, Ferrero A. Downstaging unresectable hepatocellular carcinoma by radioembolization using 90-yttrium resin microspheres: a single center experience. *J Gastrointest Oncol* 2020; **11**: 84-90 [PMID: 32175109 DOI: 10.21037/jgo.2019.06.01]

82 **O’Leary C**, Mahler M, Soulen MC. Curative-Intent Therapies in Localized Hepatocellular Carcinoma. *Curr Treat Options Oncol* 2020; **21**: 31 [PMID: 32193784 DOI: 10.1007/s11864-020-0725-3]

83 **Cescon M**, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. *J Hepatol* 2013; **58**: 609-618 [PMID: 23041304 DOI: 10.1016/j.jhep.2012.09.021]

84 **Ince V**, Ara C, Yilmaz S. Malatya and Other Criteria for Liver Transplantation in Hepatocellular Carcinoma. *J Gastrointest Cancer* 2020; **51**: 1118-1121 [PMID: 32860615 DOI: 10.1007/s12029-020-00484-y]

85 **Grant D**, Fisher RA, Abecassis M, McCaughan G, Wright L, Fan ST. Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation? *Liver Transpl* 2011; **17 Suppl 2**: S133-S138 [PMID: 21634006 DOI: 10.1002/lt.22348]

86 **Kahraman AS**. Editorial for “MRI-based Radiomics: Potential Abilities for Individual Preoperative Predictions of the Recurrence-Free Survival of Patients With Hepatocellular Carcinoma Treated With Conventional Transcatheter Arterial Chemoembolization”. *J Magn eason Imaging* 2020; **52**: 474-475 [PMID: 32579764 DOI: 10.1002/jmri.27258]

87 **MacParland SA**, Liu JC, Ma XZ, Innes BT, Bartczak AM, Gage BK, Manuel J, Khuu N, Echeverri J, Linares I, Gupta R, Cheng ML, Liu LY, Camat D, Chung SW, Seliga RK, Shao Z, Lee E, Ogawa S, Ogawa M, Wilson MD, Fish JE, Selzner M, Ghanekar A, Grant D, Greig P, Sapisochin G, Selzner N, Winegarden N, Adeyi O, Keller G, Bader GD, McGilvray ID. Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. *Nat Commun* 2018; **9**: 4383 [PMID: 30348985 DOI: 10.1038/s41467-018-06318-7]

88 **Wang S**, Zheng Y, Liu J, Huo F, Zhou J. Analysis of circulating tumor cells in patients with hepatocellular carcinoma recurrence following liver transplantation. *J Investig Med* 2018; **66**: 1-6 [PMID: 29632031 DOI: 10.1136/jim-2017-000655]

89 **Amado V**, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. *J Hepatocell Carcinoma* 2019; **6**: 1-10 [PMID: 30613572 DOI: 10.2147/JHC.S174549]

90 **Daher S**, Massarwa M, Benson AA, Khoury T. Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. *J Clin Transl Hepatol* 2018; **6**: 69-78 [PMID: 29607307 DOI: 10.14218/JCTH.2017.00031]

91 **Villanueva A**, Llovet JM. Targeted therapies for hepatocellular carcinoma. *Gastroenterology* 2011; **140**: 1410-1426 [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006]

92 **Delire B**, Stärkel P. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. *Eur J Clin Invest* 2015; **45**: 609-623 [PMID: 25832714 DOI: 10.1111/eci.12441]

93 **Ibrahim N**, Yu Y, Walsh WR, Yang JL. Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). *Oncol Rep* 2012; **27**: 1303-1311 [PMID: 22323095 DOI: 10.3892/or.2012.1675]

94 **Wilhelm SM**, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. *Mol Cancer Ther* 2008; **7**: 3129-3140 [PMID: 18852116 DOI: 10.1158/1535-7163.MCT-08-0013]

95 **Ma L**, Chua MS, Andrisani O, So S. Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives. *World J Gastroenterol* 2014; **20**: 333-345 [PMID: 24574704 DOI: 10.3748/wjg.v20.i2.333]

96 **Zhang Y**. Detection of epigenetic aberrations in the development of hepatocellular carcinoma. *Methods Mol Biol* 2015; **1238**: 709-731 [PMID: 25421688 DOI: 10.1007/978-1-4939-1804-1\_37]

97 **Mansour LA**, El Raziky M, Mohamed AA, Mahmoud EH, Hamdy S, El Sayed EH. Circulating Hypermethylated RASSF1A as a Molecular Biomarker for Diagnosis of Hepatocellular Carcinoma. *Asian Pac J Cancer Prev* 2017; **18**: 1637-1643 [PMID: 28670882 DOI: 10.22034/APJCP.2017.18.6.1637]

98 **Kojima K**, Takata A, Vadnais C, Otsuka M, Yoshikawa T, Akanuma M, Kondo Y, Kang YJ, Kishikawa T, Kato N, Xie Z, Zhang WJ, Yoshida H, Omata M, Nepveu A, Koike K. MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. *Nat Commun* 2011; **2**: 338 [PMID: 21654638 DOI: 10.1038/ncomms1345]

99 **Fan DN**, Tsang FH, Tam AH, Au SL, Wong CC, Wei L, Lee JM, He X, Ng IO, Wong CM. Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b. *Hepatology* 2013; **57**: 637-647 [PMID: 22991213 DOI: 10.1002/hep.26083]

100 **Liu C**, Liu L, Shan J, Shen J, Xu Y, Zhang Q, Yang Z, Wu L, Xia F, Bie P, Cui Y, Zhang X, Bian X, Qian C. Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification. *Cancer Lett* 2013; **339**: 60-69 [PMID: 23879963 DOI: 10.1016/j.canlet.2013.07.022]

101 **Fukuhara H**, Ino Y, Todo T. Oncolytic virus therapy: A new era of cancer treatment at dawn. *Cancer Sci* 2016; **107**: 1373-1379 [PMID: 27486853 DOI: 10.1111/cas.13027]

102 **Han Y**, Chen Z, Yang Y, Jiang Z, Gu Y, Liu Y, Lin C, Pan Z, Yu Y, Jiang M, Zhou W, Cao X. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. *Hepatology* 2014; **59**: 567-579 [PMID: 23960017 DOI: 10.1002/hep.26694]

103 **Shi F**, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, Yang YP, Tien P, Wang FS. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. *Int J Cancer* 2011; **128**: 887-896 [PMID: 20473887 DOI: 10.1002/ijc.25397]

104 **Gosalia AJ**, Martin P, Jones PD. Advances and Future Directions in the Treatment of Hepatocellular Carcinoma. *Gastroenterol Hepatol (N Y)* 2017; **13**: 398-410 [PMID: 28867968]

105 **Cannon R**, Ellis S, Hayes D, Narayanan G, Martin RC 2nd. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. *J Surg Oncol* 2013; **107**: 544-549 [PMID: 23090720 DOI: 10.1002/jso.23280]

106 **Narayanan G**, Froud T, Suthar R, Barbery K. Irreversible electroporation of hepatic malignancy. *Semin Intervent Radiol* 2013; **30**: 67-73 [PMID: 24436519 DOI: 10.1055/s-0033-1333655]

107 **Cheng RG**, Bhattacharya R, Yeh MM, Padia SA. Irreversible Electroporation Can Effectively Ablate Hepatocellular Carcinoma to Complete Pathologic Necrosis. *J Vasc Interv Radiol* 2015; **26**: 1184-1188 [PMID: 26119204 DOI: 10.1016/j.jvir.2015.05.014]

108 **Cheung W**, Kavnoudias H, Roberts S, Szkandera B, Kemp W, Thomson KR. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes. *Technol Cancer Res Treat* 2013; **12**: 233-241 [PMID: 23369152 DOI: 10.7785/tcrt.2012.500317]

109 **Bhutiani N**, Philips P, Scoggins CR, McMasters KM, Potts MH, Martin RC. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC). *HPB (Oxford)* 2016; **18**: 593-599 [PMID: 27346140 DOI: 10.1016/j.hpb.2016.03.609]

**Footnotes**

**Conflict-of-interest statement:** All theauthors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** May 5, 2022

**First decision:** June 19, 2022

**Article in press:** August 25, 2022

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Turkey

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Cassese G, Italy; Li XC, China; Scurtu RR, Romania **S-Editor:** Fan JR **L-Editor:** Filipodia **P-Editor:** Fan JR

**Table 1 Features of liver transplant criteria for hepatocellular carcinoma and survival rates**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Criteria** | **Single Tm LTD in cm** | **Multiple Tm as NN** | **Multiple Tm LTD in cm** | **TTD in cm** | **AFP in ng/mL** | **PIVKA II** | **Differ.** | **MiVi** | **LTD + NN** | **TTV in cm3** | **GGT in IU/L** | **5-yr DFS criteria in, %** | **5-yr OS criteria, %** | **5-yr Recurrence criteria, %** |
| Paul-Brousse | 3 | 1-2 | 3 | - | - | - | - | - | - | - | - | 83 | 83 | - |
| Milan | ≤ 5 | 2-3 | ≤ 3 | - | - | - | - | - | - | - | - | 82 (4 yr) | 85 (4 yr) | 8 |
| UCSF | ≤ 6.5 | 2-3 | ≤ 4.5 | ≤ 8 | - | - | - | - | - | - | - | - | 75.2 |  |
| BCLC | ≤ 7 | 2-3  4-5 | ≤ 5  ≤ 7 | - | - | - | - | - | - | - | - | - | 80.2 | 23.8 |
| Extended Criteria | ≤ 7.5 | 2-3 | ≤ 5 | - | - | - | (> 5 cm with poor diff also excluded) | - | - | - |  | 76.8 (4 yr) | 82.9 (4 yr) | - |
| Berlin | ≤ 6 | No limit | ≤ 6 | ≤ 15 | - | - | - | - | - | - | - | 64 (3 yr) | 68 (3 yr) | - |
| Kyoto | ≤ 5 | 2-10 | ≤ 5 | - | - | ≤ 400 | - | - | - | - | - | - | 86.7 | 4.9 |
| Tokyo | ≤ 5 | 2-5 | ≤ 5 | - | - | - | - | - | - | - | - | 94 (3 yr) | 75 | - |
| Onaca | ≤ 6 | 2-4 | ≤ 5 | - | - | - | - | - | - | - | - | 64.6 | - | - |
| Hangzhou | ≤ 8 | - | - | ≤ 8 | - | - | - | - | - | - | - | 70.7 | 62.4 | - |
| > 8 | > 8 | ≤ 400 | Well/Moder |
| Asan | ≤ 5 | 2-6 | ≤ 5 | - | - | - | - | - | - | - | - | - | 76.3 | 13.6 (3 yr) |
| CUN | ≤ 6 | 2-3 | ≤ 5 | - | - | - | - | - | - | - | - | - | 73 | - |
| Valencia | ≤ 5 | 2-3 | ≤ 5 | ≤ 10 | - | - | - | - | - | - | - | - | 67 | 9 |
| Shangai | ≤ 9 | 2-3 | ≤ 5 | ≤ 9 | - | - | - | - | - | - | - | 52.6 | 78.1 | 10.7 |
| Kyushu | ≤ 5 | No limit | ≤ 5 | - | - | ≤ 300 | - | - | - | - | - | 87 | 82.7 | - |
| UpToSeven | ≤ 6 | - | - | - | - | - | - | Neg. | ≤ 7 | - | - | - | 71.2 | 39.9 |
| TTV/AFP28 | - | - | - | - | ≤ 400 | - | - | - | - | ≤ 115 | - | - | Approximately 60 (4 yr) | - |
| Ext Toronto | No limit | No limit | No limit | - | - | - | Well/Moder | - | - | - | - | - | 68 | 25.6 |
| AFP-TTD | ≤ 8 | - | - | ≤ 8 | ≤ 400 | - | - | - | - | - | - | 74.4 | - | 4.9 |
| Samsung | ≤ 6 | 2-7 | ≤ 6 | - | ≤ 1000 | - | - | - | - | - | - | 89.6 | - | - |
| 5-5-500 | ≤ 5 | 2-5 | ≤ 5 | - | ≤ 500 | - | - | - | - | - | - | 73.2 | 75.8 | 7.3 |
| Malatya | ≤ 6 | No limit | ≤ 6 | - | ≤ 200 | - | Well/Moder | - | - | - | ≤ 104 | - | 79.7 | - |
| Exp Malatya | ≤ 10 | No limit | ≤ 10 | - | ≤ 200 | - | - | - | - | - | ≤ 104 | - | 77.6 | - |

AFP: Alpha fetoprotein; BCLC: Barcelona Clinic Liver Cancer; CUN: Clinica Universitaria de Navarra criteria; DFS: Disease-free survival; Differ: Differentiation; GGT: Gamma glutamyl transferase; LTD: Largest tumor diameter; MiVi: Microvascular invasion; Moder: Moderate; NN: Number of nodules; OS: Overall survival; PIVKA II: Protein induced vitamin K antagonist II; Tm: Tumor; TTD: Total tumor diameter; TTV: Total tumor volume; UCSF: University of California San Francisco criteria.

**Table 2 Comparison of some improved criteria with Milan and expanded Malatya criteria on the basis of overall survival**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Within criteria** | **Overall survival, %** | | | |
| **1-yr** | **3-yr** | **5-yr** | **10-yr** |
| Milan | 88.8 | 86.2 | 81.9 | 72.5 |
| UCSF | 89 | 83 | 75 | 67 |
| Up to Seven | 90 | 86 | 78 | 69 |
| BCLC | 89 | 83 | 76 | 68 |
| ETC | 88 | 78 | 70 | 61 |
| Hangzhou | 88 | 79 | 70 | 61 |
| Malatya | 90.1 | 85.2 | 79.7 | 72.8 |

BCLC: Barcelona Clinic Liver Cancer; ETC: Extended Toronto criteria; UCSF: University of California San Francisco.

**Table 3 Scoring systems for liver transplantation in hepatocellular carcinoma and survival rates stratified according to the recurrence rates**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Scoring system** | **Scores of the parameters** | | | | | | **Post-transplant recurrence risk** | **5-yr DFS in low risk** | **5-yr OS in low risk** | **Recurrence in low risk at 5-yr** |
| AFP Model[44], 2012 | LTD: ≤ 3 cm; 3-6 cm; > 6 cm. Point: = 0; = 1; = 4 | | NN: 1-3 nodule; > 4 nodule. Point: = 0; = 2 | | AFP: ≤ 100; 100-1000; > 1000. Point: = 0; = 2; = 3 | | Total point = score (0-9): Score ≤ 2, low risk; Score > 2, high risk |  | 67.8; 47.5 | 8.8; 50.6 |
| RETREAT[45], 2017 | LTD + NVT: 0; 1.1-4.9; 5.0-9.9; ≥ 10. Point: = 0; = 1; = 2; = 3 | | MiVi: Positive. Point: = 2 | | AFP at LT: 21-99; 21-99; 100-999; ≥ 1000. Point: = 0; = 1; = 2; = 3 | | Total point = score (0-8): Score = 0; Score < 5, low risk; Score ≥ 5, high risk (RR) |  |  | 2.9; 75.2 |
| MORAL[46], 2017 | Pre-LT-MORAL: LTD > 3 cm; NLR > 5; AFP > 200. Point: = 3; = 6; = 4 | | | | Post-LT-MORAL: LTD > 3 cm; NN > 3 nodules; Grade 4 tumor; MiVi positive. Point: = 3; = 2; = 6; = 2 | | Total point = score (0-13): Score 0-2, low risk; Score 3-6, medium risk; Score 7-10, high risk; Score > 10, very high risk | 97.4; 75.1; 49.9; 22.1 |  |  |
| NYCA[47] 2018 | LTD at diagnosis: 0-3 cm; > 3-6 cm; > 6 cm. Point: = 0; = 2; = 4 | | NN at diagnosis: 1 nodule; 2-3; ≥ 4. Point: = 0; = 2; = 4 | | AFP response: AFP always < 200; Point: = 0. Responders: Max > 200-1000 to final < 200; Point: = 2. Max > 1000 to final < 1000 (must be 50% drop); Point: = 2. Nonresponders: Max > 200-400 to final > 200; Point: = 3. Max > 400-1000 to final > 200; Point: = 4. Max > 1000 to final > 1000; Point: = 6 | | Total point = score (0-14): Score 0-2, low risk; Score 3-6, acceptable risk; Score ≥ 7, high risk | 90; 70; 42 |  | Cumulative: 7; 27.5; 62.5 |
| Metroticket 2.0[48], 2018 | LTD + NN ≤ 7 and AFP ≤ 200 or LTD + NN ≤ 5 and AFP 200-400 or LTD + NN ≤ 4 and AFP 400-1000 | | | | | | Low risk | 87.4 | 78 |  |
| SNAPP[49], 2020 | LTD: ≤ 3 cm; 3-6 cm; > 6 cm. Point: = 0; = 1; = 2 | NN: 1 nodule; 2-3 nodule; ≥ 4 nodule. Point: = 0; = 1; = 2 | | AFP and PIVKA II: AFP ≤ 150 + PIVKA II ≤ 100; AFP ≤ 150 + PIVKA II > 100; AFP > 150 + PIVKA II ≤ 100; AFP > 150 + PIVKA II > 100. Point: = 0; = 1; = 2; = 3 | | PET-CT: Isometabolic; Hypermetabolic. Point: = 0; = 1 | Total point = score (0-8): Score ≤ 2, low risk; Score 3-4, medium risk; Score > 5, high risk | 97; 71; 31 |  | 3; 29; 69 |

AFP: Alpha fetoprotein; DFS: Disease-free survival; LT: Liver transplantation; LTD: Largest tumor diameter; MiVi: Microvascular invasion; NLR: Neutrophile to lymphocyte ratio; NN: Number of nodules; NVT: Number of viable tumors; NYCA: New York/California; OS: Overall survival; PET-CT: Positron emission tomography computed tomography; PIVKA II: Protein induced vitamin K antagonist II; RETREAT: Risk Estimation of Tumor Recurrence After Liver Transplant.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**